Welcome to our dedicated page for NeueHealth news (Ticker: NEUE), a resource for investors and traders seeking the latest updates and insights on NeueHealth stock.
NeueHealth Inc (NEUE) delivers technology-enabled healthcare solutions that align providers, payors, and patients through value-based care models. This news hub provides investors and healthcare professionals with timely updates on the company’s initiatives across Medicare, Medicaid, and ACA Marketplace programs.
Access curated press releases and analysis covering NeueHealth’s performance-based partnerships, care coordination advancements, and regulatory developments. Our repository tracks operational milestones that demonstrate the company’s impact on making quality healthcare accessible while managing systemic costs.
Key updates on NeueHealth’s technology deployments, provider network expansions, and public program innovations are maintained here. Content spans earnings announcements, strategic collaborations, and service model enhancements relevant to value-based care stakeholders.
Bookmark this page for centralized access to NeueHealth’s evolving role in transforming healthcare delivery. Check regularly for insights into how NEUE balances technological scalability with localized care coordination in competitive markets.
NeueHealth (NYSE: NEUE) reported its Q1 2025 financial results, marking its fifth consecutive quarter of positive Adjusted EBITDA. The company served approximately 709,000 consumers, representing a 51% increase from Q1 2024. Key metrics show 571,000 value-based consumers (up from 360,000) and 138,000 enablement services lives (up from 109,000).
However, revenue decreased to $215.8 million from $245.1 million in Q1 2024. The company reported a net loss of $10.8 million, compared to a $4.2 million loss in the previous year. Adjusted EBITDA improved significantly to $13.5 million, up from $3.7 million in Q1 2024.
NeueHealth (NYSE: NEUE) has scheduled its first quarter 2025 earnings conference call for May 8, 2025. The company will release its financial results before markets open, followed by a conference call at 8:00 AM Eastern Time.
Participants must pre-register online to receive dial-in details, including their personal access code. The company recommends joining the call 15 minutes early. The earnings presentation will be accessible through NeueHealth's Investor Relations website, with a recording available after the event.
NeueHealth (NYSE: NEUE) has reported its Q4 and full year 2024 financial results, marking its strongest financial performance to date. The company achieved positive Adjusted EBITDA for four consecutive quarters in 2024, demonstrating the success of its value-driven, consumer-centric care model.
Starting 2025, NeueHealth has expanded its consumer base to 717,000, representing a significant 48% increase compared to 2024. The company positions itself for continued strategic growth in 2025, focusing on market expansion and strengthening relationships with payors and providers to deliver a more coordinated care experience.
NeueHealth (NYSE: NEUE) has scheduled its fourth quarter and full year 2024 earnings release for March 20, 2025. The company will announce financial results before market open, followed by a conference call at 8:00 AM Eastern Time.
Participants must pre-register for the telephone conference and will receive access details via email. A webcast option will be available through the company's Investor Relations website at investors.neuehealth.com. The company recommends participants dial in 15 minutes before the call starts. Both the earnings call recording and presentation materials will be accessible on NeueHealth's Investor Relations page after the event.
NeueHealth (NYSE: NEUE) has announced a definitive merger agreement to be acquired by New Enterprise Associates (NEA) at an enterprise value of approximately $1.3 billion. Shareholders will receive $7.33 per share in cash, representing a 70% premium over the December 23, 2024 closing price. Following the transaction, NeueHealth will become privately held, with the current executive team maintaining their roles and rolling over 100% of their equity interests. NEA and 12 existing investors will continue their investments by exchanging shares for new equity interests. The merger includes a 30-day 'go-shop' period expiring January 23, 2025, and is subject to stockholder approval and regulatory clearances.
NeueHealth (NYSE: NEUE) reported Q3 2024 financial results, marking its third consecutive quarter of positive Adjusted EBITDA. Revenue reached $232.9 million in Q3 2024, down from $269.4 million in Q3 2023. The company reported a net loss of $40.4 million, significantly improved from a $547.1 million loss in Q3 2023. Value-Based Consumers served increased to 390,000 from 355,000 year-over-year. The company reaffirmed its 2024 guidance, expecting revenue of approximately $950 million and Adjusted EBITDA between $15-25 million.
NeueHealth (NYSE: NEUE) has announced the acquisition of the remaining 25% equity interest in Centrum Health, making it a wholly owned subsidiary. The transaction aims to simplify NeueHealth's corporate structure and streamline operations to support its value-driven, consumer-centric care model. According to CEO Mike Mikan, this move positions NeueHealth to create a more coordinated healthcare experience. Additional details about the transaction will be disclosed in an upcoming Form 8-K filing with the SEC.
NeueHealth, Inc. (NYSE: NEUE), a value-driven healthcare company, has announced its plans to report Third Quarter 2024 financial results on Thursday, November 7, 2024. The results will be released before the financial markets open, followed by a conference call at 8:00 AM Eastern Time.
Participants wishing to join the call via telephone must pre-register through a provided link. Upon registration, they will receive instructions on how to access the call, including dial-in details. Alternatively, a webcast of the earnings call will be available on NeueHealth's Investor Relations page at investors.neuehealth.com.
The company recommends participants dial in at least 15 minutes before the call starts. A recording of the earnings call and presentation will be made available on NeueHealth's Investor Relations page after the event concludes.
NeueHealth (NYSE: NEUE) reported solid Q2 2024 results, delivering positive Adjusted EBITDA for the second consecutive quarter. The company reaffirmed its full-year Adjusted EBITDA guidance and expects to reach the high end of its guidance range for consumers served by year-end. Key metrics include:
- Revenue: $225,991,000 (Q2 2024) vs $297,982,000 (Q2 2023)
- Net Loss: $57,698,000 (Q2 2024) vs $88,627,000 (Q2 2023)
- Adjusted EBITDA: $3,962,000 (Q2 2024) vs $7,797,000 (Q2 2023)
For 2024, NeueHealth projects:
- Revenue: ~$950 million
- NeueCare Revenue: ~$320 million
- NeueSolutions Revenue: ~$640 million
- Adjusted EBITDA: $15-25 million
The company continues to focus on advancing its value-driven model and delivering high-quality, consumer-centric care across ACA Marketplace, Medicare, and Medicaid populations.
NeueHealth, Inc. (NYSE: NEUE), a value-driven healthcare company, has announced its Second Quarter 2024 earnings conference call scheduled for August 7, 2024. The company will release its financial results before the markets open, followed by a conference call at 8:00 AM Eastern Time. Participants are encouraged to pre-register for the call and dial in at least 15 minutes early. A webcast of the earnings call will be accessible via NeueHealth's Investor Relations page, and a recording of the call and presentation will be available afterward on the same platform.
FAQ
What is the current stock price of NeueHealth (NEUE)?
What is the market cap of NeueHealth (NEUE)?
